ASCO24: Akeso’s bispecific vvonescimab faces a rocky road ahead in NSCLC
While commercial uptake may be difficult for ivonescimab, a positive regulatory decision would help validate Akeso's bispecific platform.
While commercial uptake may be difficult for ivonescimab, a positive regulatory decision would help validate Akeso's bispecific platform.
What's Your Reaction?
